Related references
Note: Only part of the references are listed.When Effective Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design
Kenneth Y. Tsai et al.
CANCER PREVENTION RESEARCH (2016)
Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm
Joanne M. Jeter et al.
CANCER PREVENTION RESEARCH (2016)
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis
Patrick M. Lynch et al.
GUT (2016)
Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells
Cong Ye et al.
JOURNAL OF IMMUNOLOGY (2016)
Changes in prostate cancer grading: Including a new patient-centric grading system
Oleksandr N. Kryvenko et al.
PROSTATE (2016)
Estrogen receptor beta as target for colorectal cancer prevention
Cecilia Williams et al.
CANCER LETTERS (2016)
Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression
Nicholas F. Evageliou et al.
CLINICAL CANCER RESEARCH (2016)
European Code against Cancer, 4th Edition: Cancer screening
Paola Armaroli et al.
CANCER EPIDEMIOLOGY (2015)
Circulating free DNA in plasma or serum as biomarkers of carcinogenesis in colon cancer
Alberto Mangano et al.
FUTURE ONCOLOGY (2015)
Combination treatment of TRAIL, DFMO and radiation for malignant glioma cells
George A. Alexiou et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Arginine Deprivation and Immune Suppression in a Mouse Model of Alzheimer's Disease
Matthew J. Kan et al.
JOURNAL OF NEUROSCIENCE (2015)
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
Giselle L. Saulnier Sholler et al.
PLOS ONE (2015)
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas
George A. Alexiou et al.
SEMINARS IN PEDIATRIC NEUROLOGY (2015)
Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling
Altaf Mohammed et al.
CANCER PREVENTION RESEARCH (2014)
CDK Inhibitors Induce Mitochondria-mediated Apoptosis Through the Activation of Polyamine Catabolic Pathway in LNCaP, DU145 and PC3 Prostate Cancer Cells
Elif Damla Arisan et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Colorectal liver metastases guidelines, tumor heterogeneity and clonal evolution: can this be translated to patient benefit?
Georgios D. Lianos et al.
FUTURE ONCOLOGY (2014)
Topical combination of diclofenac, calcipotriol, and difluoromethylornithine has beneficial effects comparable to 5-fluorouracil for the treatment of non-melanoma skin cancer in mice
Hans-Christian Pommergaard et al.
JOURNAL OF CHEMOTHERAPY (2014)
Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro
Ming Li et al.
ANTI-CANCER DRUGS (2013)
Inhibiting Cycloxygenase and Ornithine Decarboxylase by Diclofenac and Alpha-Difluoromethylornithine Blocks Cutaneous SCCs by Targeting Akt-ERK Axis
Aadithya Arumugam et al.
PLOS ONE (2013)
Unbiased Metabolite Profiling Indicates That a Diminished Thymidine Pool Is the Underlying Mechanism of Colon Cancer Chemoprevention by Alpha-Difluoromethylornithine
Mavee Witherspoon et al.
CANCER DISCOVERY (2013)
A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity
Sarah M. Kreul et al.
CANCER PREVENTION RESEARCH (2012)
Difluoromethylornithine: The Proof Is in the Polyamines
Joanne M. Jeter et al.
CANCER PREVENTION RESEARCH (2012)
Expression Profiling and Biochemical Analysis Suggest Stress Response as a Potential Mechanism Inhibiting Proliferation of Polyamine-depleted Cells
Guy Landau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
DFMO: Targeted risk reduction therapy for colorectal neoplasia
Christina M. Laukaitis et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2011)
Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice
Gerardo G. Mackenzie et al.
CANCER PREVENTION RESEARCH (2011)
Difluoromethylornithine Is a Novel Inhibitor of Helicobacter pylori Growth, CagA Translocation, and Interleukin-8 Induction
Daniel P. Barry et al.
PLOS ONE (2011)
Phase I/II clinical trial of 2-difluoromethyl-ornithine (DFMO) and a novel polyamine transport inhibitor (MQT 1426) for feline oral squamous cell carcinoma
K. A. Skorupski et al.
VETERINARY AND COMPARATIVE ONCOLOGY (2011)
Targeting Ornithine Decarboxylase for the Prevention of Nonmelanoma Skin Cancer in Humans
Craig A. Elmets et al.
CANCER PREVENTION RESEARCH (2010)
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of alpha-Difluoromethylornithine in Subjects with Previous History of Skin Cancer
Howard H. Bailey et al.
CANCER PREVENTION RESEARCH (2010)
Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma
Robert J. Rounbehler et al.
CANCER RESEARCH (2009)
Disrupting Polyamine Homeostasis as a Therapeutic Strategy for Neuroblastoma
Nicholas F. Evageliou et al.
CLINICAL CANCER RESEARCH (2009)
Combination Chemoprevention for Colon Cancer Targeting Polyamine Synthesis and Inflammation
Eugene W. Gerner et al.
CLINICAL CANCER RESEARCH (2009)
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: Results of a year-long phase IIb randomized placebo-controlled chemoprevention trial
Anne R. Simoneau et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial
Frank L. Meyskens et al.
CANCER PREVENTION RESEARCH (2008)
ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
Michael D. Hogarty et al.
CANCER RESEARCH (2008)
Assessing the polyamine metabolism of Plasmodium falciparum as chemotherapeutic target
Ingrid B. Mueller et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2008)
Photodynamic therapy: Off-label and alternative use in dermatological practice
G. Buggiani et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2008)
Polyamine analogues - an update
H. M. Wallace et al.
AMINO ACIDS (2007)
Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential
L. M. Shantz et al.
AMINO ACIDS (2007)
Role of polyamines in arginine-dependent colon carcinogenesis in ApcmMin/+ mice
Hagit F. Yerushalmi et al.
MOLECULAR CARCINOGENESIS (2006)
Inhibitors of polyamine metabolism: Review article
HM Wallace et al.
AMINO ACIDS (2004)
Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies
KT Christov et al.
EUROPEAN JOURNAL OF CANCER (2004)
Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-α gene in rat colon tumors
MA Pereira et al.
CARCINOGENESIS (2004)
Chemotherapy of human African trypanosomiasis: current and future prospects
AH Fairlamb
TRENDS IN PARASITOLOGY (2003)
Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine
N Qu et al.
BIOCHEMICAL JOURNAL (2003)
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice
SM Fischer et al.
CARCINOGENESIS (2003)
Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents
LH Tao et al.
CARCINOGENESIS (2002)
JunD stabilization results in inhibition of normal intestinal epithelial cell growth through p21 after polyamine depletion
L Li et al.
GASTROENTEROLOGY (2002)
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
MD Prados et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Polyamine depletion therapy in prostate cancer
BH Devens et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2000)